MA52257A - Compositions pharmaceutiques comprenant blautia et leur administration orale - Google Patents

Compositions pharmaceutiques comprenant blautia et leur administration orale

Info

Publication number
MA52257A
MA52257A MA052257A MA52257A MA52257A MA 52257 A MA52257 A MA 52257A MA 052257 A MA052257 A MA 052257A MA 52257 A MA52257 A MA 52257A MA 52257 A MA52257 A MA 52257A
Authority
MA
Morocco
Prior art keywords
blautia
pharmaceutical compositions
oral administration
compositions consisting
oral
Prior art date
Application number
MA052257A
Other languages
English (en)
Inventor
Noubar B Afeyan
David Berry
Johanne Kaplan
Shaila Rahman
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54782889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MA52257A publication Critical patent/MA52257A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052257A 2014-11-25 2015-11-25 Compositions pharmaceutiques comprenant blautia et leur administration orale MA52257A (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462084536P 2014-11-25 2014-11-25
US201462084537P 2014-11-25 2014-11-25
US201462084540P 2014-11-25 2014-11-25
US201562117637P 2015-02-18 2015-02-18
US201562117632P 2015-02-18 2015-02-18
US201562117639P 2015-02-18 2015-02-18
US201562162562P 2015-05-15 2015-05-15
US201562257714P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
MA52257A true MA52257A (fr) 2021-04-21

Family

ID=54782889

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041020A MA41020A (fr) 2014-11-25 2015-11-24 Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
MA052257A MA52257A (fr) 2014-11-25 2015-11-25 Compositions pharmaceutiques comprenant blautia et leur administration orale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA041020A MA41020A (fr) 2014-11-25 2015-11-24 Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Country Status (7)

Country Link
US (12) US20160271188A1 (fr)
EP (2) EP3223834B2 (fr)
CN (1) CN108135944A (fr)
AU (3) AU2015353425B2 (fr)
CA (1) CA2973223A1 (fr)
MA (2) MA41020A (fr)
WO (5) WO2016086208A1 (fr)

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2010043045A1 (fr) * 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexine et son utilisation pour le traitement de troubles inflammatoires
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US9487551B2 (en) 2011-08-08 2016-11-08 California Institute Of Technology Small molecule compounds that control mammal-pathogenic nematodes
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2892588A1 (fr) * 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Bacteries d'origine humaine qui induisent la proliferation ou l'accumulation de lymphocytes t regulateurs
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
DK3035945T3 (en) * 2013-08-22 2018-06-14 Council Scient Ind Res A PROBIOTIC COMPOSITION CONTAINING THE UNKNOWN UNKNOWN BREVI BACTERIUM CASEI AP9
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
EP3536168A3 (fr) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Formulations probiotiques et procédés d'utilisation
EP2974735A1 (fr) * 2014-07-15 2016-01-20 Institut National De La Recherche Agronomique (INRA) Propriétés anti-inflammatoires d'une protéine de surface de Propionibacterium freudenreichii
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
WO2016065075A1 (fr) 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP4529950A3 (fr) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Procédés et compositions se rapportant à un traitement microbien de troubles
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
KR101746635B1 (ko) 2014-12-08 2017-06-13 재단법인 아산사회복지재단 박테로이데스 에시디페시언스를 유효성분으로 포함하는, 대사성 질환 예방 또는 치료용 약학적 조성물
US20160206666A1 (en) * 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
US10465224B2 (en) * 2015-02-03 2019-11-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
US10383888B2 (en) * 2015-04-10 2019-08-20 University Of Massachusetts Exopolysaccharide for inflammatory disease
EP3662917A1 (fr) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR101793328B1 (ko) * 2015-07-03 2017-11-03 씨제이제일제당 (주) Ｌ-라이신 생산능을 갖는 미생물 및 이를 이용한 ｌ-라이신 생산 방법
EP3322408B1 (fr) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Nouvelle formulation pour l'élimination de pathogènes cariogènes et opportunistes dans la cavité buccale
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
KR20170032815A (ko) * 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
EP3365027B1 (fr) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Anticorps spécifiques interférant avec hu et leur utilisation comme inhibiteur de biofilm
US11685925B2 (en) * 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106852938A (zh) * 2015-12-09 2017-06-16 深圳华大基因研究院 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
PL3400285T3 (pl) 2016-01-07 2026-05-25 Native Microbials, Inc. Sposoby poprawy wytwarzania mleka poprzez podawanie konsorcjów mikrobiologicznych
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
CN107028985A (zh) * 2016-02-04 2017-08-11 深圳华大基因研究院 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3442545A4 (fr) 2016-04-11 2020-01-08 President and Fellows of Harvard College Formulations probiotiques pour améliorer les performances athlétiques
WO2017181143A1 (fr) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante
EP3445330B1 (fr) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Utilisation d'espèces à gram négatif pour traiter la dermatite atopique
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US11766461B2 (en) 2016-04-20 2023-09-26 The Board of Trustees of the Stanford Junior Compositions and methods for nucleic acid expression and protein secretion in Bacteroides
US10188709B2 (en) * 2016-04-25 2019-01-29 University Of The Sciences Compositions and methods for the treatment of phenylketonuria (PKU)
CN105943577B (zh) * 2016-04-29 2018-02-13 刘东波 植物药的微生物发酵
ES2938355T3 (es) 2016-05-05 2023-04-10 Glycom As Composición que comprende HMOS para el tratamiento de la diarrea no infecciosa
WO2017210428A1 (fr) * 2016-06-01 2017-12-07 Crestovo Llc Compositions et méthodes de traitement de maladies inflammatoires chroniques de l'intestin (mici) et d'autres troubles
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
JP6774664B2 (ja) * 2016-06-14 2020-10-28 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 退行性脳疾患の予防又は治療効果を有するアガトバキュラム属菌株及びその用途
US20200246396A1 (en) * 2016-06-22 2020-08-06 President And Fellows Of Harvard College Inhibition of colonic group 3 innate lymphoid cells
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018026604A1 (fr) * 2016-08-01 2018-02-08 Scaled Microbiomics, Llc Systèmes et procédés de modification du microbiome pour réduire le risque de maladie et les manifestations de la maladie
WO2018027274A1 (fr) 2016-08-10 2018-02-15 Monash University Métabolites pour le traitement et la prévention de maladie auto-immune
US11464810B2 (en) 2016-08-25 2022-10-11 California Institute Of Technology Ascaroside treatment of eosinophilic esophagitis
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
JP6782302B2 (ja) * 2016-09-06 2020-11-11 ビージーアイ シェンチェン クリステンセネラ菌（Ｃｈｒｉｓｔｅｎｓｅｎｅｌｌａ ｉｎｔｅｓｔｉｎｉｈｏｍｉｎｉｓ）およびその使用
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
WO2018053308A1 (fr) 2016-09-15 2018-03-22 Sun Genomics Llc Procédé universel d'extraction de molécules d'acides nucléiques à partir d'une population diverse d'un ou plusieurs types de microbes dans un échantillon
EP3518946A4 (fr) * 2016-09-27 2020-09-09 Board of Regents, The University of Texas System Procédés permettant d'améliorer le traitement par blocage du point de contrôle immunitaire en modulant le microbiome
WO2018075886A1 (fr) * 2016-10-21 2018-04-26 The University Of Chicago Compositions et procédés permettant d'induire une préservation du système immunitaire, afin de prévenir et/ou traiter des infections
US20190269740A1 (en) * 2016-10-26 2019-09-05 Nutech Ventures Use of probiotic bacterial strains and cell extracts to inhibit acidosis and liver abscesses in cattle
KR101938865B1 (ko) * 2016-11-03 2019-01-16 주식회사 쎌바이오텍 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
WO2018094190A2 (fr) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Microbiote intestinal et traitement du cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018112437A1 (fr) * 2016-12-15 2018-06-21 uBiome, Inc. Procédé et système pour caractériser des affections liées à une allergie et associées à des micro-organismes
FR3060393A1 (fr) 2016-12-16 2018-06-22 Nestle Skin Health Sa Capsule comprenant un microorganisme probiotique pour utilisation dans un dispositif de production et de distribution de compositions
JP7166280B2 (ja) * 2016-12-20 2022-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発作を抑制する組成物及び方法
EP3559257A1 (fr) * 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Composition de microbiote, à titre de marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour améliorer l'efficacité d'un traitement à base d'anticorps anti-pd1/pd-l1/pd-l2
WO2018125735A1 (fr) * 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition et procédé pour maintenir une fonction rénale saine
US11400121B2 (en) * 2017-01-05 2022-08-02 The University Of Chicago Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
AU2017394752B9 (en) * 2017-01-23 2020-05-28 Cupione Co., Ltd. Composition for preventing or treating osteoarthritis containing sialyllactose or salt thereof as active ingredient
FR3062063B1 (fr) * 2017-01-26 2019-04-19 Centre National De La Recherche Scientifique Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
US10596206B1 (en) 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
US10733214B2 (en) * 2017-03-20 2020-08-04 International Business Machines Corporation Analyzing metagenomics data
EP3378949A1 (fr) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Procédé pour déterminer l'efficacité potentielle d'un traitement anticancéreux
CN107189956B (zh) * 2017-03-30 2020-11-10 深圳大学 一种肝素酶高产菌株及其选育方法
CA3211208A1 (fr) 2017-04-03 2018-10-11 Gusto Global, Llc Conception rationnelle d'agents biotherapeutiques d'origine microbienne
WO2018194889A1 (fr) * 2017-04-17 2018-10-25 Baylor College Of Medicine Bactérie commensale en tant que nouveau traitement pour la sécheresse oculaire et le syndrome de sjögren
WO2018195078A1 (fr) * 2017-04-18 2018-10-25 The Regents Of The University Of California Conjugués d'agent antimicrobien-polymère et leurs procédés d'utilisation
MX389322B (es) * 2017-04-28 2025-03-20 Native Microbials Inc Metodos para complementar dietas con alto consumo de granos y/o alto valor energetico en rumiantes, mediante la administracion de un bioensamble sintetico de microbios, o cepas purificadas de los mismos
US11273198B2 (en) * 2017-05-04 2022-03-15 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3624818A4 (fr) 2017-05-19 2021-04-14 Memorial Sloan-Kettering Cancer Center Procédés et compositions pour réduire une infection ou une colonisation par listeria monocytogenes
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US12011469B2 (en) * 2017-05-23 2024-06-18 Vireo Systems, Inc. Parenteral delivery device and methods of use
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CA3063508A1 (fr) * 2017-05-26 2018-11-29 Holly H. Ganz Produits et procedes d'administration therapeutique de micro-organismes a des animaux non humains
US11174293B2 (en) 2017-06-02 2021-11-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2018226690A1 (fr) * 2017-06-05 2018-12-13 The University Of Chicago Biomarqueurs du microbiome de la réactivité à l'immunothérapie : utilisations diagnostiques, pronostiques et thérapeutiques de ceux-ci
JP2020523326A (ja) * 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
US11633433B2 (en) 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
AU2018309153A1 (en) * 2017-08-04 2020-03-19 Tarunmeet GUJRAL Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 腸内の抗生物質耐性菌を除菌するための組成物及び方法
US11077179B2 (en) * 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
KR101978565B1 (ko) * 2017-08-14 2019-05-15 경희대학교 산학협력단 루미노코커스 브로미 유래 풀루란 분해 효소 및 이의 용도
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
CN110869035B (zh) * 2017-08-29 2024-01-09 深圳华大生命科学研究院 沙氏别样杆菌在制备预防和/或治疗脂质代谢性相关疾病组合物中的应用
WO2019046646A1 (fr) 2017-08-30 2019-03-07 Whole Biome Inc. Methodes et compositions pour le traitement de troubles associés au microbiome
WO2019046372A1 (fr) * 2017-08-31 2019-03-07 The Regents Of The University Of Michigan Compositions et procédés permettant d'augmenter la production de butyrate
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
EP3476396A1 (fr) * 2017-10-31 2019-05-01 Institut Gustave Roussy Compositions bactériennes et cellulaires pour le traitement du cancer colorectal et procédés d'évaluation d'un pronostic pour des patients qui en souffrent
CN111601610A (zh) * 2017-11-14 2020-08-28 伊夫罗生物科学公司 使用布劳特氏菌属菌株治疗疾病的组合物和方法
WO2019113023A1 (fr) * 2017-12-04 2019-06-13 The BioCollective, LLC Probiotiques et procédés d'utilisation
EP4410954A3 (fr) * 2017-12-11 2025-01-15 Vedanta Biosciences, Inc. Compositions et procédés pour supprimer des organismes pathogènes
EP3723775A4 (fr) 2017-12-15 2022-04-13 Solarea Bio, Inc. Compositions microbiennes et méthodes de traitement du diabète de type 2, de l'obésité et du syndrome métabolique
PL246651B1 (pl) * 2017-12-19 2025-02-24 Izabela Anna Zawisza Kompozycja bakterii probiotycznych, zastosowanie kompozycji bakterii probiotycznych oraz zestaw zawierający kompozycję bakterii probiotycznych
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
WO2019136391A1 (fr) * 2018-01-05 2019-07-11 Human Longevity, Inc. Compositions probiotiques comprenant des bactéries provenant de bacteroïdes et firmicutes phyla
CN111712260A (zh) * 2018-01-31 2020-09-25 伊夫罗生物科学公司 使用毛螺菌科细菌治疗免疫病症的组合物和方法
US11090341B2 (en) 2018-02-06 2021-08-17 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
CN112105371B (zh) * 2018-02-09 2024-12-17 内斯托尔株式会社 脂多糖控制性肠道细菌及其用途
WO2019164197A1 (fr) * 2018-02-20 2019-08-29 주식회사 엠디헬스케어 Nano-vésicules dérivées de bactéries catenibacterium et utilisation associée
WO2019169160A1 (fr) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions et méthodes de traitement du cancer à l'aide de ruminococcus gnavus
WO2019169168A1 (fr) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions et méthodes de traitement du cancer à l'aide d'agathobaculum
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
WO2019178490A1 (fr) * 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions et procédés pour traiter le cancer et l'inflammation utilisant klebsiella oxytoca
WO2019178542A1 (fr) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions pour moduler des populations de microflore intestinale, améliorer l'efficacité de médicaments et traiter le cancer, leurs procédés de fabrication et leurs méthodes d'utilisation
WO2019191073A1 (fr) * 2018-03-28 2019-10-03 Trustees Of Dartmouth College Modification du microbiome intestinal dans la fibrose kystique
JP2021519763A (ja) * 2018-03-29 2021-08-12 セレス セラピューティクス インコーポレイテッド 炎症性腸疾患を治療するための組成物及び方法
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
US20190321416A1 (en) * 2018-04-18 2019-10-24 Forte Biosciences, Inc. Compositions for the treatment of skin conditions
EP3787668B1 (fr) * 2018-05-03 2023-10-25 Crigasseni AG Souches bactériennes probiotiques produisant des protéines antimicrobiennes et compositions les comprenant pour le traitement d'infections de clostridium difficile
LT3743086T (lt) * 2018-05-11 2022-06-10 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
GB2588721A (en) 2018-05-11 2021-05-05 Forte Subsidiary Inc Compositions for the treatment of skin conditions
KR20210024481A (ko) * 2018-05-24 2021-03-05 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물 및 이의 용도
US10456430B1 (en) * 2018-05-25 2019-10-29 Genmont Biotech Incorporation Lactobacillus composition for prevention and treatment of bacterial vaginosis
WO2019227418A1 (fr) * 2018-05-31 2019-12-05 深圳华大生命科学研究院 Composition et ses applications
CN112105351A (zh) * 2018-05-31 2020-12-18 金伯利-克拉克环球有限公司 用于维持健康皮肤微生物群的益生元组合物和方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4209581A1 (fr) * 2018-06-06 2023-07-12 AMVAC Hong Kong Limited Consortiums microbiens produisant de l'acide dipicolinique et procédés de sélection de microbes pour co-formulation avec des supports
AU2019287370A1 (en) * 2018-06-14 2021-01-07 4D Pharma Research Ltd Compositions comprising bacterial strains
JP7413999B2 (ja) * 2018-06-14 2024-01-16 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN109001455B (zh) * 2018-06-15 2021-09-10 天津一瑞生物科技股份有限公司 一种肺泡灌洗液样本处理液及处理检测方法
US20190388344A1 (en) * 2018-06-22 2019-12-26 Probiotech Llc Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor
EP3810798A4 (fr) * 2018-06-25 2022-07-13 Second Genome, Inc. Anaerostipes hadrus utilisé pour promouvoir la santé
FR3083545A1 (fr) 2018-07-04 2020-01-10 Institut National De La Recherche Agronomique Utilisation d'une souche de roseburia intestinalis pour la prevention et le traitement de l'inflammation de l'intestin
WO2020013239A1 (fr) * 2018-07-10 2020-01-16 学校法人慶應義塾 Bactéries intestinales ayant une capacité proliférative en réponse au d-psicose
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
MX2021001393A (es) * 2018-08-05 2021-04-12 Da Volterra Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
EP3833195A1 (fr) * 2018-08-08 2021-06-16 Mars Incorporated Produits alimentaires pour animaux de compagnie comprenant des oligosaccharides et procédés d'utilisation
CN109350629B (zh) * 2018-08-09 2021-06-01 新乡医学院 一种用于治疗酒精戒断综合征的益生菌复合制剂及其制备方法
TW202023590A (zh) * 2018-08-17 2020-07-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP7558170B2 (ja) * 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
KR20200021257A (ko) * 2018-08-20 2020-02-28 아주대학교산학협력단 유박테리움 렉탈레를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
WO2020051379A1 (fr) 2018-09-05 2020-03-12 Solarea Bio, Inc. Méthodes et compositions pour le traitement de maladie musculo-squelettiques
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
WO2020058499A1 (fr) * 2018-09-20 2020-03-26 4D Pharma Research Limited Compositions comprenant des souches bactériennes
KR102135195B1 (ko) * 2018-10-08 2020-07-17 아주대학교산학협력단 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
JP2022504185A (ja) * 2018-10-09 2022-01-13 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020079021A1 (fr) * 2018-10-15 2020-04-23 Pharmabiome Ag Consortiums de bactéries vivantes utiles pour le traitement de maladies associées au cancer, en particulier de la maladie du greffon contre l'hôte
JP2022504423A (ja) * 2018-10-19 2022-01-13 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
CN109273046B (zh) * 2018-10-19 2022-04-22 江苏东南证据科学研究院有限公司 一种基于概率统计模型的生物学全同胞鉴定方法
EP3870154A4 (fr) 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital Compositions et méthodes de prévention et de traitement de pathologies induites par des antibiotiques à l'aide de probiotiques à l'état de biofilm
WO2020087046A1 (fr) * 2018-10-26 2020-04-30 Sun Genomics Inc. Procédé universel d'extraction de molécules d'acide nucléique en provenance d'une population variée de microbes
TW202034949A (zh) * 2018-11-02 2020-10-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
EP3873503B1 (fr) 2018-11-04 2024-07-24 Figene, LLC Traitement de la cachexie à l'aide de cellules fibroblastiques et produits associés
CN109486739B (zh) * 2018-11-23 2022-02-01 上海海洋大学 一种诱导副溶血性弧菌产生左氧氟沙星耐药性的方法
US20220023419A1 (en) * 2018-11-28 2022-01-27 The Council Of The Queensland Institute Of Medical Research Inhibiting inflammation
AU2019396657A1 (en) 2018-12-12 2021-07-08 4D Pharma Research Limited Compositions comprising Parabacteroides bacterial strains for treating cancer
CN109528777A (zh) * 2018-12-25 2019-03-29 东北农业大学 由鼠李糖乳杆菌和2`-岩藻糖基乳糖组成的组合物的应用
CN109364096A (zh) * 2018-12-25 2019-02-22 浙江华康药业股份有限公司 一种木糖醇肠溶片及其制备方法和应用
CN111408343B (zh) * 2019-01-08 2022-01-28 湖南农业大学 三维立体生物炭的制备方法及其在重金属吸附中的应用
CN111410973B (zh) * 2019-01-08 2021-05-04 湖南农业大学 一种调控生物炭形貌结构的方法
CN114025620A (zh) * 2019-01-18 2022-02-08 马斯公司 用于治疗肠道生态失调的方法和组合物
US11554145B2 (en) * 2019-01-31 2023-01-17 The Chinese University Of Hong Kong Therapeutic and prophylactic treatment for colorectal cancer
CN113692281B (zh) 2019-02-04 2024-08-16 国立研究开发法人理化学研究所 皮肤病的预防、改善或治疗用医药组合物
KR102285335B1 (ko) * 2019-02-14 2021-08-04 주식회사 엠디헬스케어 로치아 속 세균 유래 나노소포 및 이의 용도
EP3930735A1 (fr) 2019-02-26 2022-01-05 The Regents of the University of Colorado, a body corporate Méthode et composition de traitement de troubles gastro-intestinaux inflammatoires
CN110055188A (zh) * 2019-03-07 2019-07-26 南京师范大学 一株产抑菌肽的多粘类芽孢杆菌xw4及其分离筛选和应用
CN109757731A (zh) * 2019-03-14 2019-05-17 广州普维君健药业有限公司 缓解乳糖不耐的益生菌组合物及其制备方法和应用
CN109749993B (zh) * 2019-03-28 2022-07-05 众合天诚细胞生物科技(吉林)有限公司 一种脐带间充质干细胞的培养方法
IL265735A (en) * 2019-03-31 2019-05-30 Biomica A microbial consortium and its uses
GB201904758D0 (en) * 2019-04-04 2019-05-22 Univ British Columbia Xyloglucan-containing prodrugs and methods of manufacture and use thereof
CN110060739B (zh) * 2019-04-26 2021-08-31 扬州大学 一种水禽pcm遗传多样性评价方法
US11884958B2 (en) 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
CA3136833A1 (fr) * 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Compositions de beta-lactamase pour le traitement de la maladie du greffon contre l'hote
TW202108153A (zh) * 2019-05-10 2021-03-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2020236621A1 (fr) 2019-05-17 2020-11-26 California Institute Of Technology Dérivés d'ascaroside et procédés d'utilisation
EP3975744A4 (fr) * 2019-05-24 2023-06-07 Superbrewed Food, Inc. Procédé et composition pour améliorer la santé d'un oiseau
US20220305063A1 (en) * 2019-05-30 2022-09-29 New York University Probiotic compositions and methods of use
WO2020247480A1 (fr) * 2019-06-03 2020-12-10 Holoclara, Inc. Compositions et méthodes d'administration de microbiote de mammifère
KR102978329B1 (ko) 2019-06-03 2026-06-17 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
EP3790545A4 (fr) * 2019-07-17 2021-07-28 Emmaus Medical, Inc. Procédés et compositions pour le traitement de la drépanocytose et de la thalassémie
CN116077533A (zh) * 2019-07-19 2023-05-09 芬奇治疗控股有限责任公司 用于治疗胃肠道病症的方法及产品
WO2021016081A1 (fr) * 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Méthodes et produits destinés au traitement de troubles gastro-intestinaux
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
WO2021020923A1 (fr) 2019-07-30 2021-02-04 주식회사 고바이오랩 Composition pour prévenir, soulager ou traiter une lésion hépatique
WO2021030198A1 (fr) * 2019-08-09 2021-02-18 Vedanta Biosciences, Inc. Compositions et méthodes pour supprimer des organismes pathogènes
CN112415156A (zh) * 2019-08-22 2021-02-26 华北制药集团新药研究开发有限责任公司 一种阿尼芬净原料药细菌内毒素的检测方法
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
US12648968B2 (en) 2019-09-09 2026-06-09 Spinalcyte Llc Fibroblast and fibroblast-immunocyte combinations for treatment of subconcussive- and concussive-associated neurological damage
CN110564643B (zh) * 2019-09-16 2021-07-09 泰安大凡神农生物有限公司 一株具有促骨髓间充质干细胞增殖作用的动物双歧杆菌及其应用
US20220347294A1 (en) * 2019-09-23 2022-11-03 The Regents Of The University Of Michigan Compositions and methods for increasing the efficacy of immunotherapies and vaccines
WO2021059241A1 (fr) * 2019-09-27 2021-04-01 The University Of British Columbia Compositions de microbiome et méthodes de traitement d'atopies
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
EP3808358A1 (fr) * 2019-10-17 2021-04-21 University College Cork-National University of Ireland, Cork Compositions microbiennes, souches et procédés
KR102485269B1 (ko) * 2019-10-18 2023-01-06 주식회사 지놈앤컴퍼니 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물
EP4048081A2 (fr) * 2019-10-21 2022-08-31 DuPont Nutrition Biosciences ApS Compositions pour la santé intestinale
US20210128643A1 (en) * 2019-10-30 2021-05-06 Seah H. Lim Micro-organismal product and method for treating sickle cell disease
KR20220116438A (ko) * 2019-11-01 2022-08-23 유티아이 리미티드 파트너쉽 암 치료를 위한 미생물총 및 대사산물의 힘 활용
CN115243697A (zh) * 2019-11-22 2022-10-25 未知君有限责任公司 包含细菌物种的组合物及其相关方法
CA3162897A1 (fr) * 2019-11-25 2021-06-03 Fitbiomics Inc. Compositions pour ameliorer une performance athletique et leurs methodes d'utilisation
JPWO2021106952A1 (fr) * 2019-11-26 2021-06-03
US20230125810A1 (en) * 2019-11-27 2023-04-27 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
US20230042960A1 (en) * 2019-12-10 2023-02-09 Northeastern University Microbial compositions and methods for treatment and detection of disease
CN110946913B (zh) * 2019-12-17 2021-01-19 河北一然生物科技有限公司 缓解便秘及痔疮的益生菌组合物
WO2021127235A1 (fr) * 2019-12-20 2021-06-24 Persephone Biosciences, Inc. Compositions pour moduler des populations de microflore intestinale, améliorer l'efficacité de médicaments et traiter le cancer, et procédés de fabrication de celles-ci et utilisation de celles-ci
EP4327815A3 (fr) * 2019-12-20 2024-05-22 Genbioma Aplicaciones, S.L. Pediococcus acidilactici cect 9879 pour la régulation du glucose dans le sang
EP3838281A1 (fr) * 2019-12-20 2021-06-23 4D Pharma Research Limited Compositions comprenant des souches bactériennes
MX2022008144A (es) 2019-12-31 2022-08-17 Air Protein Inc Composiciones alimenticias con alto contenido de proteinas.
WO2021141828A1 (fr) * 2020-01-10 2021-07-15 Assembly Biosciences, Inc. Compositions comprenant des espèces bactériennes et procédés associés
WO2021154954A1 (fr) * 2020-01-29 2021-08-05 Etheim Biotics, Llc Compositions et procédés pour traiter des biofilms, des infections et des parodontites
US12569446B2 (en) 2020-02-11 2026-03-10 Zhejiang Huakang Pharmaceutical Co., Ltd. Enteral sustained-release sugar alcohol additive and preparation method and application thereof
EP4106779A4 (fr) * 2020-02-18 2024-03-20 Memorial Sloan Kettering Cancer Center Méthodes et compositions pour identifier et traiter les sujets susceptibles de présenter le risque d'une faible survie à un cancer
EP4106794A4 (fr) * 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Procédés de traitement d'une maladie du greffon contre l'hôte
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
CN111363671B (zh) * 2020-02-26 2023-07-21 天津医科大学 一种肠道厌氧微生物培养瓶及其制备方法
CN111398582B (zh) * 2020-03-02 2022-06-14 浙江海洋大学 海鲜产品检测试剂盒及其制备方法
MX2022010931A (es) 2020-03-02 2022-09-29 Air Protein Inc Composiciones estructuradas analogas a la carne con alto contenido de proteinas.
AU2021234298A1 (en) * 2020-03-10 2022-09-29 Federation Bio Inc. Microbial consortia for the treatment of disease
KR102162470B1 (ko) 2020-03-19 2020-10-06 주식회사 비피도 비피도박테리움 슈도카테눌라튬 c-rapo (kctc13986bp), 비피도박테리움 비피덤 att (kctc13474bp) 균주를 포함하는 쇼그렌증후군 억제용 식품 조성물 및 약학 조성물
IL297052A (en) * 2020-04-07 2022-12-01 Nat Inst Biotechnology Negev Ltd Methods of improving health of young ruminants
EP3895716A1 (fr) * 2020-04-17 2021-10-20 Maat Pharma Test de prédiction de performance fmt pour guider et optimiser la gestion thérapeutique de patients atteints d'une réaction du greffon contre l'hôte (gvhd)
CN111560330B (zh) * 2020-05-12 2022-04-26 天津科技大学 一种具有免疫调节、抗炎和抗宫颈癌作用的干酪乳杆菌及应用
KR102167386B1 (ko) * 2020-05-14 2020-10-19 코스맥스 주식회사 피부 장벽 강화, 피부 보습 또는 항노화를 위한 조성물
US20230201276A1 (en) * 2020-05-21 2023-06-29 Superbrewed Food, Inc. Method of treating or preventing an infection
US20230248777A1 (en) * 2020-05-29 2023-08-10 Figene, Llc Augmentation of fibroblast cell therapy efficacy by microbiome manipulation
CN111743998A (zh) * 2020-06-04 2020-10-09 中通美雅生命健康(深圳)有限公司 用于辅助治疗肠炎组合物及其制备方法
EP4161541A4 (fr) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC Compositions physiologiquement acceptables contenant des micro-organismes ou des produits microbiens
US12447182B2 (en) 2020-06-10 2025-10-21 The Board Of Trustees Of The University Of Arkansas Swine origin probiotics that promote health and growth performance in pigs
CN111560376B (zh) * 2020-06-15 2022-03-25 浙江大学 一种特异抑制OLFM4基因表达的siRNA及其应用
TW202214273A (zh) * 2020-06-15 2022-04-16 香港中文大學 細菌在孩童發育評估和治療的應用
WO2021257604A1 (fr) * 2020-06-16 2021-12-23 Dsm Ip Assets B.V. Composition servant à réduire le risque d'infection des voies urinaires et d'infection vaginale chez les femmes
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
CN113197311B (zh) * 2020-07-03 2023-06-23 内蒙古蒙牛乳业（集团）股份有限公司 一种乳酸菌组合物及其制备方法
US20240277785A1 (en) * 2020-07-13 2024-08-22 Ajou University Industry-Academic Cooperation Foundation Composition for preventing or treating inflammatory bowel disease
EP4188400A1 (fr) * 2020-07-31 2023-06-07 PharmaBiome AG Cartographie de niche microbienne
WO2022029015A2 (fr) * 2020-08-03 2022-02-10 Universiteit Gent Compositions bactériennes présentant une activité anti-inflammatoire
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
US12553883B2 (en) 2020-09-11 2026-02-17 MarvelBiome, Inc. Methods and uses of microbiome compositions
WO2022070052A1 (fr) * 2020-09-30 2022-04-07 Alma Bio Therapeutics Thérapie par acide nucléique pour la modulation différentielle de la microflore hôte
GB202017255D0 (en) * 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
CN112322528B (zh) * 2020-11-03 2022-07-22 江南大学 一株可干预代谢综合征的鼠李糖乳杆菌及应用
CN112262918A (zh) * 2020-11-18 2021-01-26 内蒙古自治区农牧业科学院 一种饲用微生态菌剂悬浮剂及其制备方法
CN112375712A (zh) * 2020-11-25 2021-02-19 昆明理工大学 一株乳酸乳球菌及其应用
AU2021388169A1 (en) * 2020-11-25 2023-07-13 Seres Therapeutics, Inc. Designed bacterial compositions for treating graft-versus-host-disease
KR102269962B1 (ko) * 2020-12-11 2021-06-28 주식회사 바이오뱅크힐링 유박테리움 리모숨 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296290B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 비피도박테리움 아돌레센티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
US12194058B2 (en) 2021-01-06 2025-01-14 Florida Atlantic University Board Of Trustees Cancer treatment regimen using anti-parasitic compounds and gut microbiome modulating agents
CN112574929B (zh) * 2021-01-11 2022-06-07 吉林大学 一株吉林类芽孢杆菌ypg26及其医用用途
US12702687B2 (en) 2021-02-08 2026-08-11 LISCure Bio Inc. Pharmaceutical composition for preventing or treating cholestatic liver injury comprising Leuconostoc citreum strain as active ingredient
WO2022184802A1 (fr) * 2021-03-05 2022-09-09 Dsm Ip Assets B.V. Procédé d'augmentation de la population de blautia spp. dans le microbiome intestinal
EP4306119A4 (fr) * 2021-03-08 2025-03-19 Juntendo Educational Foundation Composition et agent d'amélioration présentant une action d'inhibition de l'inflammation
JPWO2022191182A1 (fr) * 2021-03-08 2022-09-15
EP4304557A4 (fr) * 2021-03-12 2025-04-02 MarvelBiome, Inc. Procédés et utilisations de compositions, de composants ou de métabolites du microbiome pour le traitement de troubles oculaires
JPWO2022202904A1 (fr) * 2021-03-25 2022-09-29
CN113081987B (zh) * 2021-04-29 2022-03-25 药大制药有限公司 一种氟胞嘧啶片剂及其制备方法
US20240207403A1 (en) * 2021-04-29 2024-06-27 Evolve Biosystems, Inc. Personalized immunotherapy using intestinal metabolites
EP4341382A4 (fr) * 2021-05-10 2025-04-30 Microba Ip Pty Ltd Composés et méthodes de traitement de maladies
WO2022241163A1 (fr) * 2021-05-13 2022-11-17 Bcd Bioscience, Inc. Procédés d'utilisation de compositions d'oligosaccharides pour moduler le microbiote et leurs produits métaboliques, et en tant qu'agents thérapeutiques pour des applications de santé
AU2022284272A1 (en) * 2021-06-01 2023-12-07 International N&H Denmark Aps Bacterial strains for use in preventing, treating and/or reducing symptoms associated with a rhinovirus-induced cold infection
CN113337444A (zh) * 2021-06-26 2021-09-03 北京大学深圳研究院 一株弯曲芽孢杆菌及其产pha的应用
EP4362961A1 (fr) * 2021-06-28 2024-05-08 Vedanta Biosciences, Inc. Procédés de colonisation par un microbiome, de traitement et/ou de prévention d'une maladie intestinale inflammatoire et d'une maladie du greffon contre l'hôte
US20230034247A1 (en) * 2021-07-06 2023-02-02 Agency For Science, Technology And Research Method and composition for treating or decreasing gut microbiome dysbiosis induced by a prior antibiotic treatment
JP2024529325A (ja) * 2021-07-10 2024-08-06 マイクローバ アイピー ピーティーワイ リミテッド 疾患を治療するための組成物及び方法ｉｉ
WO2023010074A1 (fr) * 2021-07-28 2023-02-02 The Texas A&M University System Compositions de vaccin comprenant des souches de brucella et leurs procédés
KR102351146B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331485B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113444673B (zh) * 2021-08-17 2022-06-07 河南省科学院生物研究所有限责任公司 一株戈氏红球菌yksw-6及其应用
WO2023064443A1 (fr) * 2021-10-13 2023-04-20 Cornell University Compositions antimicrobiennes
US20240415900A1 (en) * 2021-10-20 2024-12-19 City Of Hope Clostridium butyricum compositions and methods of using the same
CN113718047B (zh) * 2021-11-04 2022-02-18 艾德范思(北京)医学检验实验室有限公司 荧光定量方法检测人母乳内10属细菌的试剂盒及其应用
AU2022386238A1 (en) * 2021-11-12 2024-06-27 Gelesis S.r.l. Compositions and methods for modulating the intestinal microbiome
EP4436407A1 (fr) 2021-11-22 2024-10-02 Solarea Bio, Inc. Méthodes et compositions pour le traitement de maladies musculo-squelettiques, le traitement d'une inflammation et la prise en charge de symptômes de la ménopause
CN113929221B (zh) * 2021-11-22 2023-07-14 宁波大学 一种用于处理水产养殖尾水的微生物复合菌群
AU2022401678A1 (en) * 2021-12-02 2024-07-04 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
JP2025503459A (ja) * 2021-12-16 2025-02-04 アルヴィアラス バイオ，インコーポレイテッド 疾患の治療のための噴霧乾燥された吸入可能なバイオ治療剤
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
KR20230112561A (ko) * 2022-01-20 2023-07-27 가톨릭대학교 산학협력단 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물
CN114470154B (zh) * 2022-01-27 2023-11-07 华南理工大学 一种甜杏仁油糖蛋白酚酸纳米肠道益生菌促进剂及其制备和应用
EP4482332A1 (fr) * 2022-02-23 2025-01-01 Société des Produits Nestlé S.A. Compositions et procédés pour réduire l'apparition de diarrhée en favorisant blautia obeum dans le microbiote intestinal
BE1030385B1 (fr) * 2022-03-24 2023-10-23 Bellavie Capsules à usage par voie orale comprenant une formulation à base de probiotiques, conditionnées en dose unitaire dans un emballage-coque stratifié
CN114848662B (zh) * 2022-04-12 2023-06-27 亿药科技(苏州)有限公司 纳他霉素在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用
CN114854778B (zh) * 2022-04-15 2023-05-30 青岛农业大学 一种岩藻多糖酶基因Fcn1及其应用
WO2023225667A2 (fr) * 2022-05-20 2023-11-23 Synlogic Operating Company, Inc. Bactéries recombinantes pour la production d'acide indole-3-acétique (aia) et leurs utilisations
CN115109718B (zh) * 2022-05-25 2023-09-12 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一株屎肠球菌菌株及其用途
CN114854884A (zh) * 2022-05-27 2022-08-05 山东农业大学 用属水平的粪便微生物预警或无创诊断脂肪肝奶牛的方法
CN115992084A (zh) * 2022-08-18 2023-04-21 吉林农业大学 表达牛巨噬细胞粒细胞集落刺激因子的重组乳酸菌及应用
US20240139263A1 (en) * 2022-10-26 2024-05-02 Synbiotic Health, Inc. Screening probiotic strains for in vitro gas production to identify strains that reduce in vivo (human) bloating and related conditions
WO2024097608A2 (fr) * 2022-10-31 2024-05-10 University Of Washington Peptides et probiotiques ciblés pour la réduction ou l'augmentation de lymphocytes t mémoires à réaction croisée d'auto-antigènes bactériens pour traiter le cancer ou une maladie auto-immune
CN115852001A (zh) * 2022-11-23 2023-03-28 深圳海关动植物检验检疫技术中心 一种小麦病原菌检测方法及其应用
FR3142656B1 (fr) * 2022-12-05 2025-07-18 Antony Cheudjeu D-xylose dans la prévention ou le traitement du COVID19, du VIH et du diabète
EP4687930A2 (fr) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Utilisation de compositions bactériennes synthétiques pour un traitement infectieux
CN121038800A (zh) * 2023-03-03 2025-11-28 科·汉森有限公司 包含卷曲乳杆菌、鼠李糖乳杆菌、詹氏乳杆菌、格氏乳杆菌和2’-岩藻糖基乳糖的组合物
EP4676495A1 (fr) * 2023-03-03 2026-01-14 Chr. Hansen A/S Compositions à base de lactobacillus reuteri, lactobacillus rhamnosus, et 2 '-fucosyllactose
CN116746681A (zh) * 2023-04-23 2023-09-15 上海交通大学医学院附属瑞金医院 一种鲍氏梭菌(Clostridium bolteae)的应用
EP4719594A1 (fr) * 2023-05-31 2026-04-08 Glyciome, LLC Diminution des populations d'acinetobacter dans le microbiome
WO2024249585A1 (fr) * 2023-05-31 2024-12-05 The Regents Of The University Of California Compositions et méthodes de traitement de troubles mentaux et métaboliques
EP4727564A2 (fr) * 2023-06-13 2026-04-22 The University of Chicago Compositions et procédés pour la dysbiose du microbiome
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
WO2025064645A1 (fr) * 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions et méthodes de traitement des maladies inflammatoires chroniques de l'intestin
CN117511772B (zh) * 2023-10-13 2025-01-10 健合香港有限公司 一株动物联合乳杆菌及其应用
EP4548928A1 (fr) 2023-10-31 2025-05-07 Institut de Recerca i Tecnologia Agroalimentaries (IRTA) Rothia nasimurium ou fraction immunomodulatrice de celui-ci dans la prévention et/ou le traitement d'une infection ou d'une maladie non infectieuse chez un sujet
CN120060478B (zh) * 2023-11-30 2026-03-31 华中农业大学 一种约氏副拟杆菌在卵巢衰老中的应用
CN117821307B (zh) * 2023-12-25 2026-06-30 江南大学 一株同时改善阴道黏膜损伤与抑制阴道炎症的约氏乳杆菌及其后生元
WO2025229092A1 (fr) * 2024-04-30 2025-11-06 N.V. Nutricia Combinaison symbiotique pour jeunes enfants
CN118987051A (zh) * 2024-09-13 2024-11-22 南方医科大学南方医院 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用
CN121171589A (zh) * 2024-09-23 2025-12-19 北京三元食品股份有限公司 基于肠道菌群评估婴幼儿发育状态的方法、系统和应用
WO2026064795A1 (fr) * 2024-09-23 2026-03-26 Northeastern University Compositions comprenant des vésicules anti-inflammatoires et procédés d'utilisation
CN119028513B (zh) * 2024-10-28 2025-01-14 一诺康(天津)科技发展有限公司 一种用于细菌耐药监测的实时监测方法、设备及存储介质
WO2026099624A1 (fr) * 2024-11-06 2026-05-15 Maat Pharma Composition pharmaceutique comprenant des bactéries enrobées d'iga pour la prévention et le traitement de la gvh
FR3169079A1 (fr) 2024-12-04 2026-06-05 Innovation Labo Technologies Sl Complexe de métabolites issus de la fermentation de grenade Punica granatum de la variété Royal Rubis comprenant de l’urolithine et du glutathion
CN119662487B (zh) * 2025-01-03 2026-07-14 江南大学 一株基于多靶点实现抗衰作用的卷曲乳杆菌及其转化甘草增效的应用
CN120324472B (zh) * 2025-06-18 2025-09-02 上海究本生物科技有限公司 一种合生元组合物及其用途
CN120643732B (zh) * 2025-08-19 2025-10-24 重庆百亚卫生用品股份有限公司 嗜酸乳杆菌la88后生元组合物以及在制备调节阴道微生态的产品中的应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
WO1993018163A2 (fr) 1992-03-13 1993-09-16 The Rockefeller University Apport et expression d'une proteine de surface hybride sur la surface de bacteries gram positif
US5411934A (en) 1990-11-30 1995-05-02 Kumiai Chemical Industry Co., Ltd. Alkanoic acid amide derivative or its salt, process for producing the same and herbicidal composition
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
DE10006989A1 (de) 2000-02-16 2001-08-23 Nutricia Nv Antiadhäsive Kohlenhydratmischung
FR2808689B1 (fr) * 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
WO2002018614A1 (fr) 2000-08-30 2002-03-07 Amano Enzyme Inc. Methode visant a augmenter le rendement d'oligosaccharides contenant $g(a)-galactosyle et compositions anti-candida
EP1239032A1 (fr) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Bactéries lactiques en tant qu'agents pour le traitement et la prévention des allergies
DE10153553A1 (de) 2001-07-07 2003-06-12 Henkel Kgaa Nichtwäßrige "3in1"-Geschirrspülmittel II
EP1364586A1 (fr) 2002-05-24 2003-11-26 Nestec S.A. Produits probiotiques et tolérance orale
CN100528169C (zh) 2002-05-31 2009-08-19 天野酶株式会社 抗炎剂、变应性疾病预防剂或改善剂及功能性食品
AU2004233658B2 (en) 2003-03-13 2009-10-29 Kirin Holdings Kabushiki Kaisha Antiallergic composition
JP3850397B2 (ja) 2003-08-12 2006-11-29 株式会社雄水 カラス撃退装置及びその製造方法
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
PL1733730T3 (pl) 2003-10-24 2008-12-31 Nutricia Nv Oligosacharydy immunomodulujące
JP4740866B2 (ja) 2003-10-24 2011-08-03 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
US20070128303A1 (en) 2004-02-06 2007-06-07 The University Of Chicago Anti-inflammatory, cytoprotective factor derivable from a probiotic organism
JP2006067881A (ja) 2004-09-01 2006-03-16 Nichimo Co Ltd 新規乳酸菌と乳酸菌製剤
JP2006104107A (ja) 2004-10-04 2006-04-20 Nichimo Co Ltd 抗食物アレルギー剤
WO2006063592A1 (fr) 2004-12-14 2006-06-22 Alk Abelló A/S Préparations pharmaceutiques comprenant une cellule bactérienne présentant un composé protéique hétérologue
US7627437B2 (en) 2005-01-14 2009-12-01 Idaho Research Foundation Categorization of microbial communities
PL2805625T5 (pl) 2005-02-28 2023-03-13 N.V. Nutricia Kompozycja odżywcza z prebiotykami i probiotykami
JP2007055986A (ja) 2005-08-26 2007-03-08 Sankyo Lifetech Co Ltd 抗アレルギー剤
KR101344432B1 (ko) 2006-01-20 2013-12-26 고리츠다이가쿠호징 오사카후리츠다이가쿠 수용성 크실란에 의한 난용성 또는 불용성 물질의 용매에 대한 친화성 향상
AU2007267560B2 (en) 2006-05-26 2010-10-21 Nestec S.A. Methods of use and nutritional compositions of Touchi Extract
US20090118226A1 (en) 2006-05-30 2009-05-07 Kazunari Ushida Intestinal eosinophil-suppressing composition
WO2008031438A2 (fr) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'organismes non pathogènes
DE502008000599D1 (de) 2007-02-14 2010-06-10 Alstom Technology Ltd Verfahren zum betrieb einer kraftwerksanlage
ES2473625T3 (es) 2007-10-26 2014-07-07 Brenda E. Moore Composición probi�tica y métodos para inducir y mantener la pérdida de peso
SI2244734T1 (sl) 2008-02-01 2016-11-30 Murdoch Childrens Research Institute Postopek induciranja tolerance na alergen
WO2009157759A1 (fr) 2008-06-23 2009-12-30 N.V. Nutricia Composition nutritionnelle destinée à améliorer le système immunitaire des mammifères
WO2010036876A2 (fr) 2008-09-25 2010-04-01 New York University Compositions et procédés de caractérisation et de restauration du microbiote gastro-intestinal, cutané et nasal
EP2216036A1 (fr) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus NCC4007, mélange probiotique et contrôle de poids
WO2010141143A2 (fr) 2009-04-21 2010-12-09 Vivocure, Inc. Souches bactériennes avirulentes génétiquement modifiées et utilisations dans des traitements médicaux
KR20120022795A (ko) 2009-04-22 2012-03-12 후지필름 가부시키가이샤 장내 세균총 구성 비율 조정제
US20100310514A1 (en) 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
WO2011022542A2 (fr) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration de facteurs normalement présents dans une niche microbienne pour améliorer la santé
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
EP2308498A1 (fr) 2009-09-30 2011-04-13 Nestec S.A. Administration de bifidobacterium rapide au cours de l'enfance pour empêcher une inflammation postérieure au cours de la vie
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
CN102939391A (zh) 2010-03-01 2013-02-20 国家农艺研究院 炎症性肠病的诊断方法
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
AU2011229969A1 (en) 2010-03-24 2012-09-20 Nestec S.A. Methods for enhancing the palatability of comestible compositions
WO2011137249A1 (fr) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Formulations prébiotiques et méthodes d'utilisation
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
CA2807242C (fr) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions pour une transplantation florale de matieres fecales et leurs procedes de fabrication et d'utilisation et dispositifs pour leur administration
WO2012024638A2 (fr) * 2010-08-20 2012-02-23 New York University Compositions et méthodes de traitement de l'obésité et de troubles associés par la caractérisation et la restauration du microbiote bactérien de mammifère
US20120135127A1 (en) 2010-11-29 2012-05-31 Sheng Chun Tang Pharmaceutical Industrial Co., Ltd. Dispersion having particles of ganoderma lucidum
WO2012142605A1 (fr) 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
EP2756071B1 (fr) * 2011-09-14 2017-12-20 University Of Guelph Compléments de milieu et procédés de culture de microorganismes anaérobies gastro-intestinaux humains
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DK2750682T3 (en) * 2011-10-11 2016-08-22 Achim Biotherapeutics Ab A composition comprising anaerobically cultured human intestinal flora
CA2892588A1 (fr) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Bacteries d'origine humaine qui induisent la proliferation ou l'accumulation de lymphocytes t regulateurs
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
CN104918624A (zh) 2012-11-26 2015-09-16 托马斯·朱利叶斯·波洛迪 恢复排泄物微生物群的组合物及其制造和使用方法
WO2014088982A1 (fr) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Traitement et prévention du dysfonctionnement de la barrière intestinale
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
WO2014159609A1 (fr) 2013-03-14 2014-10-02 Allergen Research Corporation Préparations à base d'arachide et leurs utilisations
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
US20140271718A1 (en) 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel type 1 diabetes vaccines, and methods of use
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2014201037A2 (fr) * 2013-06-10 2014-12-18 New York University Procédés permettant de manipuler des réponses immunitaires par altération du microbiote
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
AU2014359705A1 (en) 2013-11-25 2016-05-05 Nestec S.A. Heat-treated formulation of Bifidobacterium lactis NCC 2818 reduces allergic manifestations
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2935254A1 (fr) 2014-02-20 2015-08-27 MicroBiome Therapeutics LLC Fibre de gousse de soja activee
US10925953B2 (en) 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
IL251844B2 (en) 2014-10-23 2024-04-01 Roussy Inst Gustave Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
US11369646B2 (en) 2014-10-29 2022-06-28 Biogaia Ab Use of L. reuteri for recovery of microbiota dysbiosis in early life
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201505364D0 (en) 2015-03-27 2015-05-13 Genetic Analysis As Method for determining gastrointestinal tract dysbiosis
EP3297727A1 (fr) 2015-05-21 2018-03-28 Yeda Research and Development Co. Ltd Populations bactériennes pour favoriser la santé
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
WO2017115001A1 (fr) 2015-12-31 2017-07-06 Servicio Andaluz De Salud Procédé d'identification d'individus susceptibles d'être atteints de diabète
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
CN110267663A (zh) 2016-12-06 2019-09-20 卡莱多生物科技有限公司 聚糖聚合物及其相关方法
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains

Also Published As

Publication number Publication date
EP3223834A2 (fr) 2017-10-04
WO2016086205A8 (fr) 2016-08-04
US20180169153A1 (en) 2018-06-21
WO2016086209A1 (fr) 2016-06-02
EP3223834B2 (fr) 2023-07-12
US20160143962A1 (en) 2016-05-26
WO2016086210A1 (fr) 2016-06-02
CN108135944A (zh) 2018-06-08
WO2016086205A3 (fr) 2016-09-22
AU2021204574B2 (en) 2025-06-05
AU2015353425B2 (en) 2021-04-08
US9603878B2 (en) 2017-03-28
AU2015353425A1 (en) 2017-07-13
US9610307B2 (en) 2017-04-04
US20200061129A1 (en) 2020-02-27
US20160193258A1 (en) 2016-07-07
AU2021204574A1 (en) 2021-07-29
US20220323511A1 (en) 2022-10-13
WO2016086208A1 (fr) 2016-06-02
US11612622B2 (en) 2023-03-28
WO2016086210A8 (fr) 2016-07-14
US10980845B2 (en) 2021-04-20
CA2973223A1 (fr) 2016-06-02
US20160199424A1 (en) 2016-07-14
WO2016086206A8 (fr) 2016-07-07
HK1244683A1 (en) 2018-08-17
WO2016086206A1 (fr) 2016-06-02
MA41020A (fr) 2017-10-03
US10869903B2 (en) 2020-12-22
US20180071344A1 (en) 2018-03-15
US20160143961A1 (en) 2016-05-26
WO2016086205A2 (fr) 2016-06-02
US20160235792A1 (en) 2016-08-18
US20180015130A1 (en) 2018-01-18
US20160271188A1 (en) 2016-09-22
EP3223834B1 (fr) 2020-05-06
US11607432B2 (en) 2023-03-21
EP3747450A1 (fr) 2020-12-09
WO2016086209A8 (fr) 2016-06-30
US11672834B2 (en) 2023-06-13
AU2025226698A1 (en) 2025-11-13
US20190336543A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
MA50541A (fr) Formulations pharmaceutiques
LT2986304T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP3355954A4 (fr) Méthodes et compositions d'administration
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
EP3280421A4 (fr) Compositions pharmaceutiques pour thérapie combinée
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
EP3541385A4 (fr) Formulations pharmaceutiques
PL4335517T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
ME03483B (fr) Letermovir amorphe et ses formulations pharmaceutiques solides pour administration orale
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK3727555T3 (da) Oral delivery of active drug substances
EP3316685A4 (fr) Compositions pharmaceutiques lyophilisées
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
EP3675860A4 (fr) Pyrimidines substituées, compositions pharmaceutiques et méthodes thérapeutiques associées
EP2968368A4 (fr) Administration crânienne de substances pharmaceutiques
EP3203995A4 (fr) Compositions et méthodes d'administration d'agents thérapeutiques
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
MA49837A (fr) Compositions pharmaceutiques
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
EP3337463A4 (fr) Formulations pharmaceutiques
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning